Alex Biese

CURE® editors discuss data from the European Society of Medical Oncology Annual Congress, and how it could lead to new therapies being approved.

Amanda Smith, a registered nurse with Huntsman Cancer Institute, explained the impact early satiety can have on patients with MPNs and why communication with their care team is important.

According to the Food and Drug Administration, the shortage of Novartis’ prostate cancer treatment Pluvicto, which began in March, has been resolved, with the manufacturer expecting a continued expansion of supply.

Excellent adherence to hormonal therapy among patients with ductal carcinoma in situ plays a key role in reducing risk of future tumors, researchers found.

Dr. Gene G. Finley of Drexel University of College of Medicine and AHN Cancer Institute, Allegheny Clinic Medical Oncology, explains why the approval of Braftovi and Mektovi “It's an important improvement in our armamentarium.”

One expert explains why palliative care for patients with cancer “is about aligning the patient's goals and the family's goals with the therapeutic goals.”

An expert explains the recent movement towards the use of immunotherapy for patients with resectable NSCLC.

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news.

Sally Joy Wolf, who has metastatic breast cancer, tells CURE about how some patients can feel adrift during the annual October “sea of pink.”

“When people see me, they just feel like they have to start jogging,” as one chief nurse practitioner tells CURE when discussing how patients with MPNs can reduce their risk of cardiovascular and thrombotic events.

Researchers found that non-White patients with gastrointestinal cancers, particularly those living in areas with persistent poverty, face inequities in access to and dosage of opioids for end-of-life pain relief.

Patients with cancer and diabetes need to carefully co-manage both diseases, as one expert tells CURE.

A childhood cancer specialist discusses how oncology drug shortages may affect the treatment of children with cancer.

The brain cancer vaccine SurVaxM is among the novel treatments currently being studied for patients with glioblastoma.

Interim findings from the phase 2 ASPEN-06 clinical trial show evorpacept’s potential for treatment of patients with HER2-positive gastric/gastroesophageal junction cancer.

Laura Shinn and Jenna Cavalero, both former childhood patients of the Children’s Hospital of New Orleans, reflect on how their cancer journeys inform their work with patients today.

Braftovi (encorafenib) with Mektovi (binimetinib) has been approved for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, the agency announced on Wednesday evening.

Findings from the CheckMate 649 trial “further support the use of (Opdivo) plus chemotherapy as a tolerable and efficacious first-line treatment” for some patients, according to researchers.

A diagnosis of a rare internal form of melanoma left J.B. Ward and her care team in “a whirlwind of confusion,” but she pushed for aggressive forms of treatment.

Results from the phase 3 NAPOLI trial show survival benefits for patients with metastatic pancreatic ductal adenocarcinoma treated with Onivyde plus oxaliplatin, leucovorin and fluorouracil.

Oral microbiome “plays an important role” in patterns of oral mucositis, an after-effect experienced by nearly all patients with head and neck cancer treated with chemotherapy and radiotherapy.

For Maggie Cambora, who received a diagnosis of acute myeloid leukemia in 2020, the third potential donor match was the connection that saved her life, she told CURE®.

One doctor tells CURE why the FDA’s approval of the TKI Bosulif to treat children with chronic myelogenous leukemia “is really important.”

Now in its fifth edition, “The Complete Guide to Breast Reconstruction: Choosing the Best Options After Your Mastectomy” by two-time breast cancer survivor Kathy Steligo offers patients comprehensive, up-to-date information.

Interim results of a trial displayed promising results for patients with ovarian cancer treated with IMNN-01 with neoadjuvant chemotherapy and a PARP inhibitor.

“Full-time mom, full-time hairdresser, full-time wife” Maggie Cambora, who received a diagnosis of acute myeloid leukemia in 2020, received a stem cell transplant.

A phase 2 trial found that some patients with classical Hodgkin lymphoma saw a nearly 74% probability of second remission due to retreatment with Keytruda.

The BRAF inhibitor AMB-1310 is currently being studied in both the United States and China for the treatment of patients with glioblastoma who are carrying the BRAF V600E mutation.

When both a patient and their loved one acting as their caregiver are facing cancer, “there has to be proper care for both,” one expert tells CURE®.

Lifestyle changes and remedies such as topical estrogen can be of assistance to cancer survivors dealing with hormone deficiencies, as one expert tells CURE.